Inhaled hormones (ICS) are currently the most effective drugs for the treatment of asthma and have become the first-line drugs for the long-term treatment of asthma; the pharmacological action of ICS is based on the local anti-inflammatory activity of the airways. However, at least theoretically, ICS is not a cure for asthma and does not provide good symptom control in moderate-to-severe persistent asthma, which requires the combination of second-line asthma treatment drugs such as long-acting β2 agonists. Even so, some “refractory” asthma is still not effectively controlled. From a pharmacokinetic and pharmacodynamic point of view, the current ICS is still unsatisfactory. Their dose-effect curves are too flat in the medium-to-high dose range recommended by GINA. That is, increasing the dose of ICS results in a very limited increase in efficacy. In contrast, the curves for dose and systemic effects are steeper. Moderate doses of ICS produce some systemic effects such as suppression of adrenocortical function. The systemic effects are more pronounced with long-term use of high doses of ICS. Therefore, the development of new therapeutic drugs and methods to further improve our current treatment is still the direction of future efforts. First, the new ICS 1, Mometasone furoate (mometasone furoate, MF): is a new ICS launched by Schering-Plough in recent years, its steroid parent ring structure is similar to beclomethasone propionate, the difference in the D ring with the furoate group instead of BDP dipropionate structure, is currently one of the strongest anti-inflammatory activity ICS. MF’s anti-inflammatory activity exceeds BUD, roughly equal to or slightly stronger than FP. Bousquet et al. reported that the efficacy of MF in the treatment of moderate persistent asthma was even better than that of BUP 800 μg/d at a dose of 400 μg/d. Moreover, MF was more effective in mild-moderate asthma when administered once daily at 200-400 μg/d. The dose-efficacy relationship study of MF showed a trend towards better efficacy of MF 400 μg/d compared to 200 μg/d, but 800 μg/d did not show better efficacy compared to 400 μg/d. Therefore, the literature recommends 400 μg/d as the ideal dose for moderate persistent asthma. In terms of safety, the systemic bioavailability of MF has been reported.